MedTrace Logo

A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study

NCT05955235 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2023-11-28

No results posted yet for this study

Summary

This is a long-term safety follow-up study of the Phase I/IIa multicenter study of SCM-AGH in subjects with moderate to severe acute pancreatitis. subjects will be followed up for a maximum period of 240 weeks after the first dose of investigational product. Only subjects previously enrolled in protocol SCM-APT2001 (ClinicalTrials.gov ID: NCT04189419) will be eligible for this long-term follow-up protocol.

Conditions

  • Pancreatitis, Acute

Interventions

OTHER

Not Applicable(Observation Study)

Not Applicable(Observation Study)

Sponsors & Collaborators

  • SCM Lifescience Co., LTD.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-10
Primary Completion
2026-08-20
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05955235 on ClinicalTrials.gov